Brown Advisory
BMY.RT

Brown Advisory’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Brown Advisory’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,680
Closed -$29K – 1128
2020
Q4 		$29K Sell
18,680
-870
-4% -$1.85K ﹤0.01% 1011
2020
Q3 		$40K Buy
19,550
+67
+0.3% +$191 ﹤0.01% 954
2020
Q2 		$71K Buy
19,483
+107
+0.6% +$386 ﹤0.01% 926
2020
Q1 		$57K Sell
19,376
-1,199
-6% -$3.95K ﹤0.01% 917
2019
Q4 		$59K Buy
+20,575
New +$53.5K ﹤0.01% 1023

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Brown Advisory's BMY.RT Position: Q1 2021 in Review

Brown Advisory sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 18,680 shares — an estimated $29K sold.

Brown Advisory first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $71K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Brown Advisory reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Brown Advisory sold 18,680 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $29K.
  • Brown Advisory first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Brown Advisory's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $71K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Brown Advisory's 13F filing for Q1 2021, filed 14 May 2021.